Home / Ingredients / Alpha-lipoic acid (ALA)
Some evidence for reducing sensory symptoms of diabetic peripheral neuropathy; evidence does not justify generic blood-sugar or weight-management claims.
NCCIH notes that alpha-lipoic acid may reduce pain associated with diabetic neuropathy but has not been shown to be helpful for blood-sugar control. A 2023 meta-analysis of oral ALA found improvements in symptom scores but not several objective neurologic measures.
Diabetic-neuropathy trials often use hundreds of milligrams per day, including 600–1,800 mg/day in oral studies. Outcomes and studied populations should not be generalized to healthy users.
ALA can cause gastrointestinal or other adverse effects and may interact with glucose-lowering therapy. Evidence from clinical populations should be interpreted with medical context.
NOURISH+, S-BALANCE, and VITALPRO list alpha-lipoic acid but do not publish a study-matched ALA dose. Finished-product neuropathy, glucose, or weight claims remain unverified.
Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review (Systematic review and meta-analysis of randomized controlled trials; PMID 37630823)
Population/scope: 10 randomized trials; 1,242 people with diabetic sensorimotor peripheral neuropathy
Evidence scope: Neuropathy symptom and neurologic scores
Finding: Oral alpha-lipoic acid improved total symptom scores and some neurologic disability measures, while several objective or secondary outcomes were not improved.
Limitations: The evidence applies to diabetic polyneuropathy rather than general glucose control or weight loss; several outcomes were null and some pooled estimates were heterogeneous.
Directness: Relevant human evidence · verified 2026-10-02
Important: Ingredient-level evidence is not proof that a finished product has the same effect. Dose, form, population, duration, and formulation must match.
For informational purposes only; not individualized medical advice.